extended its license to Linguamatics’ I2E interactive information extraction system with a further multiyear deal. The company has been a customer of Linguamatics
since 2003. I2E uses natural language processing-based text-mining technology to provide insights from literature sources in real-time. The platform supports decision making at many points in the drug discovery process including target selection, biomarker discovery, and safety/toxicology.